At ByBug, we are redefining how the world produces therapeutic proteins. Our breakthrough lies in a new paradigm of biomanufacturing: a platform powered by genetically enhanced Hermetia illucens larvae engineered to produce recombinant proteins and veterinary therapeutics with unprecedented efficiency. By transforming insect larvae into next-generation biofactories, we enable a production model that is 100× more cost-effective and up to 150× more sustainable than conventional systems—unlocking a future where life-saving and life-enhancing biomolecules can be manufactured at scale, with…
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.